OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Pain and Therapy (2021) Vol. 10, Iss. 1, pp. 637-650
Open Access | Times Cited: 18
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Pain and Therapy (2021) Vol. 10, Iss. 1, pp. 637-650
Open Access | Times Cited: 18
Showing 18 citing articles:
Setting higher standards for migraine prevention: A position statement of the International Headache Society
Simona Sacco, Messoud Ashina, Hans‐Christoph Diener, et al.
Cephalalgia (2025) Vol. 45, Iss. 2
Closed Access | Times Cited: 1
Simona Sacco, Messoud Ashina, Hans‐Christoph Diener, et al.
Cephalalgia (2025) Vol. 45, Iss. 2
Closed Access | Times Cited: 1
OnabotulinumtoxinA: Still the Present for Chronic Migraine
Carlo Baraldi, Flavia Lo Castro, Raffaele Ornello, et al.
Toxins (2023) Vol. 15, Iss. 1, pp. 59-59
Open Access | Times Cited: 12
Carlo Baraldi, Flavia Lo Castro, Raffaele Ornello, et al.
Toxins (2023) Vol. 15, Iss. 1, pp. 59-59
Open Access | Times Cited: 12
Evidence-based guidelines for the pharmacological treatment of migraine
Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access
Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management
Patricia Pozo‐Rosich, Alicia Alpuente, Stephen D. Silberstein, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 9, pp. 555-568
Closed Access | Times Cited: 3
Patricia Pozo‐Rosich, Alicia Alpuente, Stephen D. Silberstein, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 9, pp. 555-568
Closed Access | Times Cited: 3
BAY-117082-driven NLRP3 inflammasome inhibition resolves nitro-glycerine (NTG) neuronal damage in in vivo model of migraine
Alessia Filippone, Sarah Adriana Scuderi, Rossella Basilotta, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113851-113851
Open Access | Times Cited: 15
Alessia Filippone, Sarah Adriana Scuderi, Rossella Basilotta, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113851-113851
Open Access | Times Cited: 15
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors
Raffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10975-10975
Open Access | Times Cited: 14
Raffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10975-10975
Open Access | Times Cited: 14
Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study
Claudia Altamura, Nicoletta Brunelli, Giovanna Viticchi, et al.
Toxins (2023) Vol. 15, Iss. 4, pp. 284-284
Open Access | Times Cited: 7
Claudia Altamura, Nicoletta Brunelli, Giovanna Viticchi, et al.
Toxins (2023) Vol. 15, Iss. 4, pp. 284-284
Open Access | Times Cited: 7
Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions
Loredana Raciti, Gianfranco Raciti, David Militi, et al.
Journal of Integrative Neuroscience (2022) Vol. 21, Iss. 5
Open Access | Times Cited: 12
Loredana Raciti, Gianfranco Raciti, David Militi, et al.
Journal of Integrative Neuroscience (2022) Vol. 21, Iss. 5
Open Access | Times Cited: 12
Utility of Repetitive Transcranial Magnetic Stimulation for Chronic Daily Headache Prophylaxis: A Systematic Review and Meta-Analysis
Emily Stephens, Chathurika S. Dhanasekara, Víctor Montalván, et al.
Current Pain and Headache Reports (2024) Vol. 28, Iss. 4, pp. 149-167
Closed Access | Times Cited: 2
Emily Stephens, Chathurika S. Dhanasekara, Víctor Montalván, et al.
Current Pain and Headache Reports (2024) Vol. 28, Iss. 4, pp. 149-167
Closed Access | Times Cited: 2
Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
K Kollewe, Charly Gaul, Astrid Gendolla, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 13
K Kollewe, Charly Gaul, Astrid Gendolla, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 13
OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study
Claudia Altamura, Raffaele Ornello, Fayyaz Ahmed, et al.
Journal of Neurology (2022) Vol. 270, Iss. 2, pp. 986-994
Closed Access | Times Cited: 9
Claudia Altamura, Raffaele Ornello, Fayyaz Ahmed, et al.
Journal of Neurology (2022) Vol. 270, Iss. 2, pp. 986-994
Closed Access | Times Cited: 9
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Pain and Therapy (2021) Vol. 10, Iss. 2, pp. 1605-1618
Open Access | Times Cited: 10
Raffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Pain and Therapy (2021) Vol. 10, Iss. 2, pp. 1605-1618
Open Access | Times Cited: 10
Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine
Luigi Francesco Iannone, Davide Fattori, Martina Marangoni, et al.
CNS Drugs (2023) Vol. 37, Iss. 2, pp. 189-202
Closed Access | Times Cited: 3
Luigi Francesco Iannone, Davide Fattori, Martina Marangoni, et al.
CNS Drugs (2023) Vol. 37, Iss. 2, pp. 189-202
Closed Access | Times Cited: 3
Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA
Enrique Martínez‐Pías, Ángel Luis Guerrero Peral, Álvaro Sierra, et al.
Toxins (2021) Vol. 13, Iss. 6, pp. 432-432
Open Access | Times Cited: 6
Enrique Martínez‐Pías, Ángel Luis Guerrero Peral, Álvaro Sierra, et al.
Toxins (2021) Vol. 13, Iss. 6, pp. 432-432
Open Access | Times Cited: 6
The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine: understanding from diverse patient profiles in a single session
Elif Ilgaz Aydınlar, Tuba Erdoğan Soyukibar, Pınar Yalinay Dikmen
Frontiers in Neurology (2024) Vol. 15
Open Access
Elif Ilgaz Aydınlar, Tuba Erdoğan Soyukibar, Pınar Yalinay Dikmen
Frontiers in Neurology (2024) Vol. 15
Open Access
Physicians’ Practice of the Non-Cosmetic Uses of Botulinum Toxin: A Cross-Sectional Study in Saudi Arabia
Sarah A Alzarah, Huda Alabasi, Lujain T Alanazi, et al.
Cureus (2022)
Open Access | Times Cited: 1
Sarah A Alzarah, Huda Alabasi, Lujain T Alanazi, et al.
Cureus (2022)
Open Access | Times Cited: 1
A UTILIZAÇÃO DA TOXINA BOTULÍNICA DO TIPO A PARA TRATAMENTO DA ENXAQUECA CRÔNICA: Uma revisão de literatura
Anne Nascimento
Revista Saúde dos Vales (2023) Vol. 7, Iss. 1
Open Access
Anne Nascimento
Revista Saúde dos Vales (2023) Vol. 7, Iss. 1
Open Access
De la cefalea crónica diaria a la migraña crónica: historia, epidemiología y tratamiento
Enrique Martínez Pías
(2021)
Open Access
Enrique Martínez Pías
(2021)
Open Access
